Frontlight ResearchEarly access
Not yet taking people in SpainPhase 1
Tests TT125-802 with other cancer drugs in advanced lung cancer
Tests TT125-802 combined with other drugs in adults with advanced non-small cell lung cancer.
Key facts
- Who runs it
- TOLREMO therapeutics AG
- Where
- Barcelona, Madrid, and Pozuelo de Alarcón, SpainSee the 3 sites
- Trial code
- Registry title
- An Open-label, Multicenter, Phase 1a/1b Study to Evaluate the Safety and Anti-tumor Activity of TT125-802 in Combination With Adagrasib, Osimertinib or Docetaxel in Patients with Advanced NSCLC
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 40 people, planned
- Started
- 1 Mar 2026
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional
- Record updated
- 1 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced non-small cell lung cancer (NSCLC). It tests TT125-802 together with adagrasib, osimertinib or docetaxel.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Advanced NSCLC
Main reasons for not taking part
- Healthy volunteers cannot join.
Where in Spain
- Hospital Quirónsalud BarcelonaBarcelona, SpainNot yet recruiting
- Hospital Universitario 12 de OctubreMadrid, SpainNot yet recruiting
- Hospital Universitario Quironsalud MadridPozuelo de Alarcón, SpainNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Tests TT125-802 with other cancer drugs in advanced lung cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 1 June 2026